

Association of mRNA expression of iron  
metabolism-associated genes and progression of  
non-alcoholic steatohepatitis in rats

日本大学医学部内科学系消化器肝臓内科学分野

樋口 晃久

申請年 2019年

指導教員 森山 光彦

## Association of mRNA expression of iron metabolism-associated genes and progression of non-alcoholic steatohepatitis in rats

Teruhisa Higuchi<sup>1</sup>, Mitsuhiro Moriyama<sup>1</sup>, Akiko Fukushima<sup>1</sup>, Hiroshi Matsumura<sup>1</sup>, Shunichi Matsuoka<sup>1</sup>, Tatsuo Kanda<sup>1</sup>, Masahiko Sugitani<sup>2</sup>, Akiko Tsunemi<sup>3</sup>, Takahiro Ueno<sup>3</sup> and Noboru Fukuda<sup>3</sup>

<sup>1</sup>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine, Itabashi-Ku, Tokyo 173-8610, Japan

<sup>2</sup>Department of Pathology, Nihon University School of Medicine, Itabashi-Ku, Tokyo 173-8610, Japan

<sup>3</sup>Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Itabashi-Ku, Tokyo 173-8610, Japan

**Correspondence to:** Tatsuo Kanda, **email:** kandat-cib@umin.ac.jp, kanda.tatsuo@nihon-u.ac.jp  
Mitsuhiro Moriyama, **email:** moriyama.mitsuhiro@nihon-u.ac.jp

**Keywords:** iron; NASH; SHRSP5 rat; intestine; HAMP

**Received:** May 18, 2017

**Accepted:** May 09, 2018

**Published:** May 25, 2018

**Copyright:** Higuchi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### ABSTRACT

**Background:** Excess iron is associated with non-alcoholic steatohepatitis (NASH).

**Results:** mRNA expression of duodenal cytochrome b, divalent metal transporter 1, ferroportin 1, hepcidin, hephaestin and transferrin receptor 1 in liver were higher in high fat, high cholesterol-containing diet (HFCD) group than in normal diet (ND) group. mRNA levels of divalent metal transporter 1 and transferrin receptor 1, which stimulate iron absorption and excretion, were enhanced in small intestine. Epithelial mucosa of small intestine in HFCD group was characterized by plasma cell and eosinophil infiltration and increased vacuoles. Iron absorption was enhanced in this NASH model in the context of chronic inflammation of small intestinal epithelial cells, consequences of intestinal epithelial cell impairment caused by HFCD. Iron is transported to hepatocytes via portal blood, and abnormalities in iron absorption and excretion occur in small intestine from changes in iron transporter expression, which also occurs in NASH liver. Knockdown of hepcidin antimicrobial peptide led to enhanced heavy chain of ferritin expression in human hepatocytes, indicating association between hepcidin production and iron storage in hepatocytes.

**Conclusions:** Iron-related transporters in liver and lower/upper portions of small intestine play critical roles in NASH development.

**Methods:** Expression of iron metabolism-related genes in liver and small intestine was analyzed in stroke-prone spontaneously hypertensive rats (SHR-SP), which develop NASH. Five-week-old SHR-SP fed ND or HFCD were examined. mRNA and protein levels of iron metabolism-related genes in liver and small intestine from 12- and 19-week-old rats were evaluated by real-time RT-PCR and immunohistochemistry or Western blot.

### INTRODUCTION

Recently, the number of non-alcoholic steatohepatitis (NASH) cases and the number of cases with NASH-associated hepatocellular carcinoma (HCC) have increased

[1–4]. However, the mechanism of disease progression remains unclear. It is considered that NASH is associated with various factors including lifestyle-associated issues such as obesity and diabetes mellitus (DM). In particular, it has been reported that these additional factors include

genetic abnormalities, in addition to oxidative stress, high lipid peroxide levels, excess iron, insulin resistance and increased proinflammatory cytokine levels [5, 6].

The liver is supplied by portal blood flow from the intestine. It is reasonable to assume therefore that various substances from the intestine are involved in the pathology of liver diseases. Thus, the intestinal microenvironment also plays a role in the development of NASH and non-alcoholic fatty liver disease (NAFLD). The importance of the microbiome-gut-liver axis has long been recognized in human and rodent models [7–9]. Lipopolysaccharide (LPS), a product of gut bacteria, also influences the pathology of NASH [9–13].

In previous studies [14, 15], we investigated iron metabolism and liver pathology and reported that the progression of hepatitis C and the development of HCC are closely associated with iron metabolism. During the past few years, among the parameters evaluated as possible predictors of NAFLD, serum ferritin has emerged [16]. The expression levels of iron metabolism-related genes may affect the development of NASH. The environment of the small intestine, which is the site of iron absorption, may also influence iron metabolism.

Under normal conditions, mammalian cells acquire most of their iron from the plasma protein transferrin (Tf), which can deliver iron to cells and has a high affinity for binding to the plasma membrane protein Tf receptor 1 (TfR1) [17]. The main iron uptake transporter is the ferrous ion membrane transport protein divalent metal transporter 1 (DMT1) [17]. Solute carrier family 40 member 1 (SLC40A1)/ferroportin 1 (FPN1) essentially functions as an iron efflux transporter [17]. A ferric reductase that can deliver ferrous iron to DMT1 in the gut is duodenal cytochrome B (Dcytb), whose expression is enhanced by stimuli that enhance iron absorption [18]. Hepcidin is one of the regulators of iron release into plasma. In the small intestine, the copper-containing protein ceruloplasmin homolog hephaestin is required for efficient iron absorption, and animals with defective hephaestin function are anemic [18]. Cellular iron homeostasis is regulated by the iron transporters DMT1 and FPN1 and by the iron storage protein ferritin.

Spontaneously hypertensive rats (SHR) and stroke-prone spontaneously hypertensive rats (SHRSP) are well established parallel lines from outbred Wistar-Kyoto (WKY) rats [19, 20]. SHRSP5/Dmcr rats, a substrain of SHRSP, appear to be a useful model for analyzing the time-dependent changes of high fat, high cholesterol-containing diet (HFCD)-induced steatohepatitis and fibrosis progression [21, 22].

In the present study, we developed a NASH model using SHRSP5 rats fed HFCD and investigated the changes in mRNA expression of iron metabolism-related genes in the liver and the upper and lower parts of the small intestine. We found an association between the mRNA expression of iron metabolism-related genes and

the progression of NASH. We also observed an association between the production of hepcidin and storage of iron in hepatocytes. We found iron-related transporters in the liver and in the lower and upper parts of the small intestine play critical roles in the development of NASH.

## RESULTS

### Comparisons of body, liver and spleen weights

The mean body weights of the ND and HFCD groups were 117.0 g and 114.5 g, respectively, at the beginning of the study, and at 7, 9, 11, 13, 15, 17 and 19 weeks of age were 198.1 g and 123.9 g, 237.3 g and 166.9 g, 282.3 g and 209.3 g, 289.9 g and 217.8 g, 307.0 g and 229.0 g, 294.3 g and 245.5 g and 336.8 g and 253.7 g, respectively. Body weight increase was less in the HFCD group than in the ND group. Of note, it was observed that all rats in the HFCD group frequently had diarrhea and became weaker over the course of the study.

Mean liver weights in the ND and HFCD groups at 12 and 19 weeks of age were 11.3 g and 23.5 g and 13.6 g and 34.6 g, respectively. Mean liver weight was significantly greater in the HFCD group than in the ND group at both 12 and 19 weeks of age ( $p<0.05$  and  $p<0.05$ , respectively). Mean spleen weights in the ND and HFCD groups at 12 and 19 weeks of age were 0.53 g and 0.78 g and 0.5 g and 1.4 g respectively. Mean spleen weight was significantly greater in the HFCD group than in the ND group at both 12 and 19 weeks of age ( $p<0.05$  and  $p<0.05$ , respectively).

### Iron content of liver and small intestine

We compared the amounts of iron in the liver and small intestine. The amount of iron in the livers of the HFCD group ( $9.58\pm 0.94$  ppb,  $n=4$  at 12 weeks of age and  $11.13\pm 1.44$  ppb,  $n=3$  at 19 weeks of age) was significantly lower than that in the 5-week-old control group ( $20.2\pm 5.25$  ppb,  $n=4$ ;  $p<0.05$ ) and that in the ND group at 12 and 19 weeks of age ( $19.0\pm 2.82$  ppb,  $n=4$ ;  $p<0.05$  and  $26.2\pm 2.92$  ppb,  $n=4$ ;  $p<0.05$ , respectively). Similarly, the amount of iron in the small intestine in the HFCD group ( $7.25\pm 0.070$  ppb,  $n=4$ ) was significantly lower than that in the ND group ( $8.45\pm 0.35$  ppb,  $n=4$ ;  $p<0.05$ ).

### Biochemical blood examination

Serum total bilirubin,  $\gamma$ -glutamyl transferase and free fatty acid levels at 19 weeks of age were significantly higher in the HFCD group than in the ND group. The serum total cholesterol level was significantly higher in the HFCD group than in the ND group at 12 weeks of age. Serum aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase levels at both 12 and 19 weeks of age were significantly higher in the HFCD group than in the ND group (Table 1).

**Table 1: Biochemical examination of blood samples obtained from normal diet (ND) and high fat and high cholesterol-containing diet (HFCD) groups at 5, 12 and 19 weeks of age**

Parameters	week 5	week 12			week 19		
		ND (n=4)	HFCD (n=4)	<i>p-value</i> <sup>a</sup>	ND (n=4)	HFCD (n=3)	<i>p-value</i> <sup>b</sup>
AST (U/L)	251.75±19.97	167.50±8.96	587.00±167.40 <sup>c</sup>	0.0012	276.75±82.43	976.00±203.07 <sup>c</sup>	0.0001
ALT (U/L)	49.00±3.16	55.50±4.20	432.25±194.25 <sup>c</sup>	0.0003	79.25±4.65	587.67±27.68 <sup>c</sup>	0.0001
ALP (U/L)	1847.25±375.04	838.25±67.29 <sup>c</sup>	2329.25±261.09 <sup>c</sup>	0.0001	835.00±130.95 <sup>c</sup>	2850.00±182.48 <sup>c</sup>	0.0001
γ-GT (U/L)	2.90±0.0	2.90±0.0	2.90±0.0	N.S.	2.88±0.05	6.33±1.53 <sup>c</sup>	0.0001
T.Bil (mg/dl)	0.06±0.01	0.06±0.01	0.05±0.01	N.S.	0.05±0.01	0.24±0.17 <sup>c</sup>	0.0092
D.Bil (mg/dl)	0.03±0.01	0.02±0.01	0.02±0.01	N.S.	0.00±0.01	0.13±0.10 <sup>c</sup>	0.0028
T.Chol (mg/dl)	86.75±7.68	56.00±1.41	226.75±28.40	0.00002	65.50±4.66	715.67±302.32 <sup>c</sup>	0.0001
TG (mg/dl)	67.75±15.82	95.25±13.43	38.25±4.65	N.S.	84.25±22.34	90.00±76.39	N.S.
FFA (μEq/L)	512.50±113.81	499.75±143.19	591.25±73.09	N.S.	705.50±144.02	1267.00±325.29 <sup>c</sup>	0.0046

AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γ-GT, γ-glutamyl transferase; T.Bil, total bilirubin; D.Bil, direct bilirubin; T.Chol, total cholesterol; TG, triglycerides; FFA, free fatty acids; Data are shown as mean ± SD. For each parameter, the Tukey-Kramer test was used for comparisons among the 5-week-old group and 12- and 19-week-old rats from the ND and HFCD groups. N.S., no statistically significant difference; <sup>a</sup>ND versus HFCD groups; <sup>b</sup>ND versus HFCD groups; <sup>c</sup>p<0.05, compared with 5-week groups.

### Pathological findings in liver

In the ND group, liver fibrosis of the liver was not observed at either 12 or 19 weeks of age (Supplementary Figure 1A). Diffuse lipid droplets were seen in hepatocytes at both 12 and 19 weeks of age. However, perisinusoidal, pericellular and perivenular fibrosis, and ballooning of hepatocytes, which are typical indications of NASH, were not observed in the ND group. According to Brunt's criteria for NASH [23], activity grade 1, fibrosis stage 1 and activity grade 1, fibrosis stage 2 were observed in the 12- and 19-week-old ND groups, respectively. In addition, in the HFCD group at 12 weeks of age, greater numbers of lipid droplets in the livers were observed. Mild sinusoidal fibrosis, moderate pericellular fibrosis, and moderate perivenular fibrosis were also observed (Supplementary Figure 1A), as were ballooning hepatocytes and hyalines were also observed. These observations were consistent with NASH (activity grade 1, fibrosis stage 1) according to the Brunt's criteria [23].

Necro-inflammatory reaction was severe in the parenchymal area and mild in the periportal area. Inflammatory cell infiltration in the portal area was minimal. Moderate ballooning of hepatocytes was observed. In the HFCD group, the collapse of hepatocytes was observed at both 12 and 19 weeks of age. Fibrosis of the liver in the 19-week-old HFCD group indicated further progression. Moderate to advanced perisinusoidal

fibrosis, pericellular fibrosis and perivenular fibrosis were observed. Furthermore, bridging fibrosis was also observed. These observations were consistent with NASH (activity grade 3, fibrosis stage 3) at 19 weeks of age based on the Brunt's criteria [23] (Figure 1).

Inflammatory cell infiltration was rather mild compared with that at 12 weeks of age, but there was more significant lipid droplet formation. Supplementary Figure 1B presents the characteristic changes in livers from the HFCD groups. As mentioned above, we considered that the livers from the 19-week-old HFCD group had histopathological features of NASH.

### Pathological findings of upper and lower portions of small intestine

It is assumed that the upper and lower portions of the small intestine are located near the duodenum and the ileum, respectively. In the upper segment, infiltration of inflammatory cells, including histiocytes, phagocytes and lymphocytes, was observed immediately below the mucosal epithelium in 5-week-old rats. In particular, infiltration of plasma cells was evident, and these histological features were consistent with chronic inflammation. There were a few lymphoid follicles. The nuclei of intestinal villus epithelial cells were arrayed along the bottom part of the cells, and the cell structure

remained intact. The lower portion of the small intestine revealed almost the same findings as those from the upper portion at 5 weeks of age, although inflammatory cell infiltration was more apparent.

In the upper segment of the small intestine in the 19-week-old ND group, Auerbach's plexus was maintained, and infiltration of inflammatory cells, mostly plasma cells, was observed. There was chronic inflammation, but there was no difference in terms of severity compared to 5-week-old rats. In the lower segment of the small intestine in the 19-week-old ND group, there was marked detachment of the columnar epithelium, and deformation of the stroma was evident. We considered that these findings were caused by ischemia; however, necrosis in trophoblastic cells was not observed. Further, the number of vacuolated cells had also increased.

No columnar epithelial detachment was observed in the upper part of the small intestine in the 19-week-old HFCD group. The severity of inflammatory cell infiltration was similar to that in the ND group; infiltrating cells were mostly plasma cells, followed in number by lymphocytes and histiocytes. In addition, the number of cells with cytoplasmic vacuoles was greater in the 19-week-old HFCD group than in the ND group. These cytoplasmic vacuoles were not stained by Sudan III, meaning that they were not lipid droplets.

In the lower portion of the small intestine in the 19-week-old HFCD group, mild impairment of microvilli and the columnar epithelium was observed. The tissue structure was completely maintained, although moderate inflammatory cell infiltration in the stroma and signs of chronic inflammation were observed. In addition, cells with vacuoles in the cytoplasm were observed to the same degree as in the upper portion of the small intestine.

Also, an increased number of goblet cells was observed compared with in the ND group.


### Expression of iron metabolism-related genes (IMGs) in the liver

IMG mRNA expression in the liver was examined at 5 weeks, 12 weeks and 19 weeks of age (Figure 2A). Of the IMGs, Dcytb, DMT1, TfR1, hepcidin, FPN1 and hephaestin mRNA expression increased significantly at 12 and 19 weeks of age in the HFCD group compared with the control group. Further, hephaestin mRNA levels at 19 weeks of age increased significantly compared to those at 12 weeks of age in the HFCD group. Conversely, hepcidin mRNA levels in the HFCD group were significantly higher in the 5-week-old control group but were significantly lower than those in the ND group (at both age 12 and 19 weeks). Moreover, hephaestin is the only gene with significantly increased mRNA levels between age 12 and 19 weeks.

Hepcidin is the only gene whose mRNA level increased more than the levels of the 5-week-old ND group. A significant difference in mRNA expression levels between the ND and HFCD groups was observed for Dcytb, DMT1, TfR 1, FPN1 and hephaestin. In addition, hepcidin was the only gene with significantly lower mRNA expression in the HFCD group than in the ND group.

### IMG mRNA expression in small intestine

Dcytb was the only gene with enhanced mRNA expression in the lower segment compared to the upper segment of the small intestine in the control subjects,



**Figure 1: Histological findings for the livers from 19-week-old SHRSP5 rats from the high fat, high cholesterol-containing diet (HFCD) group.** Masson's trichrome stain (1) or hematoxylin and eosin (HE) stain (2-4). Original magnification: x100 (1, 2) or x4 (3, 4). Ballooning hepatocytes and pericellular fibrosis were observed (1, 2). Enlargement of the portal vein and increased numbers of portal vein branches were observed (3). Massive necrosis (collapse) of hepatocytes was also observed (4).


whereas FPN1 was the only gene with enhanced mRNA expression in the upper segment compared to the lower segment in the control subjects (Figure 2B).

In the upper portion of the small intestine, Dcytb was the only gene that demonstrated a tendency to decrease compared to 5-week-old rats. On the other hand, DMT1, hepcidin and TfR1 showed a tendency to increase compared to 5-week-old rats (Figure 2B). In the lower portion of the small intestine, DMT1, TfR1 and hephaestin demonstrated a tendency to increase in comparison to 5-week-old rats (Figure 2B).


### Western blot analysis of iron metabolism-related proteins

Compared with the 5-week-old group, Dcytb, DMT1, TfR1 and FPN1 expression were higher, and hepcidin expression was lower in the 19-week-old HFCD group, while hephaestin expression was not changed (Figure 3A).

In the upper portion of the small intestine, Dcytb, DMT1 and FPN1 expression levels were higher in the HFCD group than in the 5-week-old group, whereas



**Figure 2: Real-time RT-qPCR analysis of the expression of iron metabolism-related genes (IMGs) in the liver and small intestine of SHRSP5 rats from the high fat, high cholesterol-containing diet (HFCD) or normal diet (ND) groups. (A) Expression of IMGs in the liver. (B) Expression of IMGs in the small intestine. Data represent mean ± standard deviation. For each parameter, the Turkey-Kramer test was used for comparisons among the 5-week-old group and the 12- and 19-week-old rats from the ND and HFCD groups. (\*P<0.05; \*\*P<0.001). FPN1, ferroportin 1; TfR1, transferrin receptor 1; DMT1, divalent metal transporter 1; Dcytb, duodenal cytochrome b; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.**



**Figure 3: Western blot analysis of iron metabolism-related proteins in the liver (A) and upper and lower portions of the small intestine (B) of SHRSP5 rats from the high fat, high cholesterol-containing diet (HFCD) or normal diet (ND) groups. FPN1, ferroportin 1; TfR1, transferrin receptor 1; DMT1, divalent metal transporter 1; Dcytb, duodenal cytochrome b; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.**

hephaestin expression was lower in the HFCD group than in the 5-week-old group. In the lower portion of the small intestine, DMT1 expression was enhanced in the HFCD group, but Dcytb and FPN1 expression levels were lower than those in the 5-week-old group (Figure 3B).

### Immunohistochemical analysis (IHC) of iron metabolism-related molecules at protein level

Next, we performed immunohistochemical (IHC) analysis to confirm the results from Western blot analyses, (Supplementary Figures 2 and 3). Comparisons of the degree of expression of the various proteins in the liver and in the upper and lower segments of the small intestine are shown in Supplementary Figures 2 and 3. At the protein level in the liver, the expression levels of Dcytb, DMT1 and FPN1 were higher in the HFCD group at 12 and 19 weeks of age than those in the 5-week-old group (Supplementary Figure 2A-2D). The expression of hepcidin was higher in the HFCD group at age 12 and 19 weeks than that at age 5 weeks. In addition, there was a marked increase in hepcidin expression in the cytoplasm as well as in the cell membrane of hepatocytes in the HFCD group. The hephaestin level in hepatocytes was greater in the HFCD group than in the ND group at both ages. In sinusoidal cells, increased DMT1, FPN1, hephaestin and hepcidin expression levels were observed in the HFCD group compared to the ND group, but differences were not statistically significant.

In the upper portion of the small intestine, Dcytb and hephaestin expression in the HFCD group tended to


be lower, and DMT1 and FPN1 expression tended to be higher in the HFCD group than in the 5-week-old group. No differences in Dcytb, DMT1, FPN1 or hephaestin expression were observed in the ND group compared with the 5-week-old group (Supplementary Figure 3A-3D).

In the lower portion of the small intestine, DMT1, FPN1 and hephaestin expression tended to be higher, and the expression of Dcytb was lower in the HFCD group than in the 5-week-old group. No differences were observed in Dcytb, FPN1, and hephaestin expression between the ND and the 5-week-old groups (Supplementary Figure 3A to 3D).

### Knockdown of hepcidin antimicrobial peptide (HAMP) induced heavy chain of ferritin (FTH) mRNA expression in human hepatoma cell lines

To confirm the association between the production of hepcidin and the storage of iron in hepatocytes, ferritin mRNA expression was examined in human hepatoma cell lines transfected with si-HAMP compared with those transfected with si-C (Figure 4A-4B). These siRNAs were validated by real-time PCR (Figure 4A). A differential regulation of the two ferritin subunits FTL and FTH has been reported [24], and also that dietary iron supplementation affected human FTH [25]. The knockdown of HAMP induced FTH expression in human hepatoma cell lines (Figure 4B).

TLR-associated signaling target PCR array was also performed using Huh7 transfected with si-HAMP and those transfected with si-C. IL1 $\beta$  and colony stimulating



**Figure 4: Effects of knockdown of hepcidin antimicrobial peptide (HAMP) on ferritin and toll-like receptor (TLR)-associated gene expression in human hepatoma cell lines.** (A) HAMP mRNA expression and (B) heavy chain of ferritin (FTH) mRNA expression were examined by RT-qPCR. (C) Changes of TLR-associated gene expression in Huh7 cells transfected with si-HAMP (siRNA against HAMP) or si-C (control siRNA). Data represent mean  $\pm$  standard deviation. \* $P < 0.05$ , compared with si-C-transfected cell lines.

factor 3 (CSF3) were upregulated 3.0-fold and 2.5-fold in Huh7 transfected with si-HAMP, compared with si-C-transfected cells ( $p=0.091$  and  $p=0.042$ , respectively). TNF and IL1 $\alpha$  were downregulated 2.3-fold and 2.2-fold in Huh7 transfected with si-HAMP ( $p = 0.070$  and  $p = 0.060$ , respectively) (Figure 4C). The expression of HAMP mRNA might be associated with cytokine gene expression in human hepatocytes.

## DISCUSSION

In livers of the 19-week-old group, it is suggested that the increased expression of DMT1 and FPN1, which are iron-related transporters, in the HFCD group enhanced the absorption and excretion of iron (Figure 2A). In addition, hepcidin expression, which is negatively regulated by promotion of the degradation of FPN1, was increased in the cytoplasm and cell membrane of hepatocytes as well as in mesenchymal cells, compared with the 5-week-old group. On this basis, the iron excretion mechanism was activated in the hepatocytes of the HFCD group. Furthermore, it is suggested that an increase in the reduction to Fe<sup>2+</sup>, as well as the oxidization of excreted Fe<sup>2+</sup>, was positively regulated by increased Dcytb and hephaestin expression (Figure 2A).

Expression of the iron reductase gene Dcytb in the lower portion of the small intestine of the 19-week-old group was less in the HFCD group than in the 5-week-old group, and Dcytb expression also tended to be less in the upper portion of the small intestine (Figure 2B). On the other hand, a high level of FPN1 expression was observed in only the upper portion of the small intestine, both DMT1 and TfR1 expression levels were higher in both the upper and lower portions, and hephaestin expression was higher in only the lower portion in the HFCD group (Figure 2B). Based on these results, it was confirmed that the uptake and excretion of iron were increased in the upper portion of the small intestine in the HFCD group. Additionally, in the lower portion of the small intestine, it was confirmed that Fe<sup>2+</sup> uptake was increased and oxidation of excreted Fe<sup>2+</sup> was increased in the HFCD group. As mentioned above, iron absorption and iron excretion were stimulated in intestinal epithelial cells of the HFCD group by increased expression of DMT1 and FPN1, as well as the increased expression of TfR1, which is an iron receptor.

Dcytb expression in the upper part of the small intestine tended to be lower in the HFCD group (Figure 2B); therefore, it was confirmed that the reduction from Fe<sup>3+</sup> to Fe<sup>2+</sup> is suppressed, which makes the uptake of Fe<sup>2+</sup> into intestinal epithelial cells difficult. In addition, it is assumed that the oxidation of Fe<sup>2+</sup> excreted from the basal membrane side of intestinal epithelial cells was not stimulated because there was no change in hephaestin expression.

On the other hand, the results from the upper segment of the small intestine differed slightly from those of the lower segment. In the lower segment of the small intestine of the HFCD group, both Dcytb and FPN1 expression levels decreased over time; while DMT1 expression increased, as did hephaestin expression (Figure 2B). Therefore, we confirmed that the reduction of Fe<sup>3+</sup> is regulated in an inhibitory manner, but the absorption of iron is regulated in a stimulatory manner in the lower part of the small intestine; in addition, the oxidation of Fe<sup>2+</sup> excreted from the basal membrane side of intestinal epithelial cells acted in a stimulatory manner. On this basis, it is assumed that the host transfers Fe<sup>2+</sup>, which binds iron as a complex to solid organs such as the liver.

Expression of iron metabolism-related proteins tended to be increased in intestinal epithelial cells that were histologically damaged or degenerated. We observed that the absorption and excretion of iron were stimulated in epithelial cells of the upper segment of the small intestine and that the absorption of iron was stimulated in epithelial cells of the lower segment of the small intestine, but excretion was suppressed in the HFCD group. We found that the reduction of Fe<sup>3+</sup> was stimulated. The reduction of Fe<sup>3+</sup> was inhibited by decreased Dcytb (Figure 3B), although our data regarding protein expression were less compelling, perhaps in part because of the technical difficulties encountered in obtaining strictly comparable tissue samples.

On the other hand, in studies on IMGs in rats that develop NASH, hepcidin expression has been reported to be decreased in the liver [26] and FPN1 expression is stimulated [27]. Furthermore, it has been reported that liver diseases other than NASH may be associated with DMT1 gene polymorphisms [28] and the upregulation of Dcytb expression [29]. As mentioned above, it is assumed that iron metabolism is more complex in patients with hepatic diseases. However, there are few studies on iron absorption pathways in the small intestine [30].

Of note, hephaestin mRNA expression was markedly increased in the liver and lower small intestine. Therefore, we suppose that hephaestin has a novel activity in the onset of NASH. Furthermore, goblet cells are significantly increased in the upper and lower small intestine. We inferred that the small intestine, whose primary function is absorption, protects the mucosa by increasing mucous secretory cells, such as goblet cells, in response to exposure to substances such as HFCD.

One mechanism for the development of NASH involves LPS, a TLR4 agonist derived from enterobacterial flora; LPS reaches the liver in large amounts and increases the secretion of proinflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, by stimulating Kupffer cells [10, 13, 31]. The proportion of Lactobacilli in feces was increased in a study of the distribution of enteric bacteria in feces in an experimental NASH model created by

feeding HFCD [12]. As mentioned above, complicated mechanisms are involved in the development of NASH, and they are mediated by interactions between the intestinal tract and the liver. These mechanisms include iron metabolism. Therefore, we considered that studies on the morphology of the small intestine and IMGs are valuable for confirming the involvement of the enterohepatic relationship in the development of NASH. We believed that exposure of the small intestinal mucosa to HFCD would cause intestinal epithelial cell damage, leading to a breakdown of the absorption and excretion pathways of iron, mediated by the oxidation and reduction of iron and iron transporters and causing the development of NASH.

Regarding the morphology of the small intestine in the HFCD group, we considered that there was severe impairment of the epithelium of the small intestinal mucosa, likely through exfoliation and necrosis, as the rats in the present study displayed marked weakness caused by frequent diarrhea and weight loss. Considerable impairment of the epithelial cells was not observed, although degeneration of the small intestinal mucosa and mild exfoliation occurred. Moreover, a marked increase in the infiltration of plasma cells and an increase in eosinophil infiltration in the small intestine were observed.

As mentioned above, we considered that feeding HFCD induced inflammatory cell infiltration in the epithelium of the small intestine and increased the permeability of the mesentery and, as a result, induced abnormalities in the absorption and excretion of various metabolites such as LPS and minerals including iron. Consequently, abnormalities in the expression of iron oxidoreductase and iron transporters in small intestinal epithelial cells were induced and excess iron was transported to hepatocytes and mesenchymal cells via the portal blood flow. In addition, we assumed that abnormalities in the absorption and excretion of iron caused by abnormal expression of the receptor genes and oxidation-reduction-related genes in hepatocytes also contributed to the development of NASH.

Next, we examined the expression of IMGs in the liver. The weights of the livers were significantly greater in the HFCD group than in the ND group; however, the total amount of iron in the livers was significantly lower in the HFCD group than in the ND group. This NASH model may lead to severe impairment and degeneration of hepatocytes, which store iron intrinsically, as well as a reduced number of Kupffer cells, as lipid droplets were diffusely increased in hepatocytes. These findings are supported by the facts that increases in the production of hepcidin and FPN1 by hepatocytes would induce iron excretion and that knockdown of HAMP induced FTH mRNA expression (Figure 4B). The present study also

demonstrated an association between altered expression of IMGs in the liver of rats and the development of NASH.

Using Western blot analysis, we observed that, although the expression level of hepcidin mRNA increased, the amount of hepcidin protein in the hepatocytes decreased slightly. The exact reason for this finding remains unclear. Unfortunately, measuring and interpreting the iron content is difficult because a large amount of fat accumulates in rat livers in this NASH model. The expression level of hepcidin tended to be lower at 19 weeks of age compared with that at 12 weeks of age in the HFCD group. Our protein expression data are less compelling, perhaps in part because of the technical difficulties encountered in obtaining strictly comparable tissue samples.

When we examined intrahepatic iron ( $\text{Fe}^{3+}$ ) deposition by Prussian blue staining, we were unable to find any iron deposition in the liver in this NASH rat model. Thus, we confirmed that the presence of  $\text{Fe}^{3+}$  in the liver was extremely low in this NASH rat model. We are planning to confirm the amount of iron ( $\text{Fe}^{2+}$  and  $\text{Fe}^{3+}$ ) in the liver in future studies by applying other methods, including iron staining.

Additionally, IMG expression was examined in the small intestine. When the upper and lower segments of the small intestine were compared, differences in the expression of genes and proteins were noted. In epithelial cells in the upper segment, there was no significant change in Dcytb expression in the HFCD group, regardless of HFCD feeding. However, marked promotion of the uptake of  $\text{Fe}^{2+}$  uptake into intestinal epithelial cells due to an increase in DMT1 expression and a significant increase in TfR1 expression was seen.

On the other hand, FPN1 expression tended to be higher in the upper segment of the small intestine, and the excretion of  $\text{Fe}^{2+}$  was stimulated, whereas there was no change in hephaestin expression. Therefore, it is suggested that regulation exists to prevent the oxidization of excreted  $\text{Fe}^{2+}$  to  $\text{Fe}^{3+}$  through FPN1 in epithelial cells in the upper portion of the small intestine.

In epithelial cells in the lower portion of the small intestine, suppression of the reduction of  $\text{Fe}^{3+}$  to  $\text{Fe}^{2+}$  caused by decreased Dcytb expression, increased DMT1 expression, and increased uptake of  $\text{Fe}^{2+}$  caused by increased TfR1 expression was seen in the HFCD group. This pattern of expression was clearly different from that in the liver. On the other hand, no change was seen in hepcidin expression, while FPN1 expression decreased and hephaestin expression increased in the lower portion of the small intestine, resulting in excreted  $\text{Fe}^{2+}$  being oxidized to  $\text{Fe}^{3+}$  in epithelial cells of the upper small intestine. As mentioned above, feeding HFCD caused a decrease in Dcytb expression and increases in both DMT1 and hephaestin expression.

Under normal conditions, iron is absorbed from the gastrointestinal content of the upper segment of the small intestine. However, increases in DMT1 and TfR1 expression were also observed in the lower segment in the HFCD group. In addition, there was no change in hepcidin expression although an increase in hephaestin expression was seen. Therefore, it can be assumed that feeding HFCD increased the uptake of iron in the lower portion of the small intestine, enhanced the excretion of iron from intestinal cells to the portal circulation, and enhanced the oxidation of excreted Fe<sup>2+</sup> to Fe<sup>3+</sup>. Based on these results, we considered that iron absorption and excretion are regulated in the small intestine and liver as follows. First, prolonged intake of HFCD disrupts the intestinal flora, causing abnormal enteric bacteria to propagate. It is thought that the host reacts to prevent the propagation of abnormal enteric bacteria by actively absorbing iron into intestinal epithelial cells to reduce the level of iron that is required for their growth. Then, the host promotes iron absorption by overexpressing the genes required for the excretion of iron so that the absorbed iron is excreted into the portal blood flow. Next, to protect mucosal cells from damage from HFCD, mucus secretory cells, such as goblet cells, proliferate, and the small intestine, which is primarily an absorption organ, secretes considerable mucus to protect the small intestinal mucosa.

On the other hand, this is regulated so that the excretion of iron and the expression of genes that oxidize excreted Fe<sup>2+</sup> to Fe<sup>3+</sup> are increased. As mentioned above, it is assumed that the expression of iron metabolism-related proteins, which are involved in the absorption, transport and excretion of iron, is involved in the development of NASH in a complex manner. In particular, it is assumed that changes in enterobacterial flora caused by HFCD influence the pathophysiological state. Further studies on the relationship between the intestinal tract and the liver in the development of NASH will be needed.

Iron absorption was stimulated in this NASH model as a consequence of the impairment of intestinal epithelial cells caused by HFCD. Excess iron is transported to hepatocytes via the portal blood and abnormalities in iron absorption and excretion, caused by the altered expression of iron transporters, also occur in the hepatocytes of this NASH model. There is an association between the mRNA expression of iron metabolism-related genes and the progression of NASH. There is also an association between the production of hepcidin and the storage of iron in hepatocytes. Iron-related transporters in the liver and in both lower and upper segments of the small intestine play critical roles in the development of NASH.

In conclusion, iron absorption was stimulated in this NASH model as a consequence of the impairment of intestinal epithelial cells caused by HFCD. Excess iron is transported to hepatocytes through portal blood, and abnormalities in iron absorption and excretion, caused by the altered expression of the iron transporters, also occur in the hepatocytes of this NASH model.

## MATERIALS AND METHODS

### SHRSP5 rats

The arteriolipidosis-prone rat (ALR; SHRSP5) used in the present study is a subline obtained by feeding HFCD to SHRSP [19, 20]. These rats are characterized by fat deposition in their arteries and fibrosis of the liver, leading to the development of diet-induced NASH. When SHRSP5 rats were fed HFCD, blood biochemical and liver histological findings were comparable to those of rats fed a stroke-prone (SP) diet at weeks 8 and 14 [20]. Based on these experiments, we created a NASH rat model by feeding HFCD, which consisted of 68% (w/w) SP diet (Funabashi Farm, Chiba, Japan), 25% (w/w) palm oil, 5% (w/w) cholesterol and 2% (w/w) cholic acid, to ALRs in accordance with the experimental protocol previously described [21, 22].

The normal diet (ND) group was fed only the SP diet. These rats arrived at our laboratory at 4 weeks old and were used for the experiments after being fed ND for 1 week in our laboratory. This investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 1996). The Ethics Committee of Nihon University School of Medicine examined all research protocols involving the use of animals and approved this study.

### Biochemical blood examination

See Supplementary Material.

### Histological examination

Initially, 4 SHRSP5 rats each from the HFCD and ND groups were sacrificed by exsanguination under anesthesia using sodium pentobarbital (Nembutal, 50 mg/kg IP; DS Pharma Biomedical, Osaka, Japan) at week 7 (12 weeks of age) or week 14 (19 weeks of age). The controls were four 5-week-old SHRSP5 rats. Blood was collected from the inferior vena cava, and serum was immediately isolated and stored at -80°C. Livers and the upper and lower segments of the small intestines were collected and divided into three portions. First, the tissues were fixed in 2.5% formalin, embedded in paraffin, and stored at 4°C. Second, the tissues were embedded in optimal cutting temperature (OCT) compound immediately after collection, rapidly frozen in a dry ice/acetone bath, and stored at -80°C until use. Finally, the remaining tissues were stored at -80°C without fixation for future use. Hematoxylin and eosin (HE) staining and Masson's trichrome staining were performed for histological examination of liver tissue. In addition, the upper and lower portions of the small intestine were observed using only HE staining (see Supplementary Material for details).

## Examination of iron metabolism-related genes

mRNA expression levels of iron metabolism-related genes (IMGs), including Dcytb, DMT1, TfR1, FPN1, hepcidin, and hephaestin, were measured by real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The mRNA expression of IMGs in the liver and upper and lower segments of the small intestine was studied and compared among the 5-week-old group and the ND and HFCD groups. Primers used in the present study are shown in Supplementary Table 1 (see Supplementary Material for details).

## Western blot analysis

Western blot analysis was performed to determine the levels of various proteins in the organs. Immunoblotting of Dcytb, DMT1, TfR1, FPN1, hephaestin, hepcidin and DMT1 was performed as previously described by Arakawa et al [32] (see Supplementary Material for details).

## Immunohistochemical analysis

Immunohistochemical (IHC) staining for proteins encoded by iron metabolism-related genes was performed using paraffin-embedded sections of liver tissue obtained from 5-, 12- and 19-week-old rats and paraffin-embedded sections of the upper and lower portions of the small intestine obtained from 5- and 19-week-old rats. Indirect IHC staining was performed for the detection of Dcytb, DMT1, FPN1, hepcidin, and hephaestin in the liver and the upper and lower portions of the small intestine (see Supplementary Material for details).

## Cell culture, transfection of siRNAs, gene expression analysis and human toll-like receptor (TLR)-associated signaling target PCR array

Human hepatoma cell lines Huh7 and HepG2 were grown in Roswell Park Memorial Institute medium (RPMI-1640) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) at 5% CO<sub>2</sub> and 37°C [33, 34]. The siRNA against HAMP (si-HAMP) and control siRNA (si-C) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Transfection of 50 nM siRNAs was performed with Effectene Transfection Reagents (Qiagen, Hilden, Germany) as previously described [34]. After 48 hours, extraction of cellular RNA, cDNA synthesis and RT-qPCR were performed based on the SYBR-Green methods, using a 7500 Fast real-time PCR system (Applied Biosystems, Foster, CA, USA) as previously described [34]. PCR amplification was performed on cDNA templates using primers specific for human actin (sense primer 5'-CAGCCATGTACGTTGCTATCCAGG-3' and antisense primer 5'-AGGTCCAGACGCAGGATGGCATG-3'), HAMP

(sense primer 5'-TGCCCATGTTCCAGAGGC-3' and antisense primer 5'-CCGCAGCAGAAAATGCAGAT-3') and FTH (sense primer 5'-AATTGGGTGACCACGTGACC-3' and antisense primer 5'-TTCCGCCAAGCCAGATTC-3') [35]. Gene expression analysis was performed using the  $\Delta\Delta CT$  (comparative cycle threshold) method [34]. We also performed a human TLR-associated signaling target PCR array according to the manufacturer's protocol [34]. The data were analyzed using PCR Array Data Analysis Software (<http://www.sabiosciences.com/pcrarraydataanalysis.php>).

## Statistical analysis

The study included 20 rats, but one was then excluded. The amount of mRNA detected and the results of biochemical examination of blood are presented as mean  $\pm$  standard deviation (SD). Statistical analyses were performed using the Tukey-Kramer test for multiple comparisons. Staining scores of tissues were analyzed using the Steel-Dwass test for multiple comparisons. A statistically significant difference was defined as  $P < 0.05$ . All statistical analyses were performed using JMP 12 (SAS Institute Inc., Cary, NC, USA).

## Abbreviations

ALR: SHRSP5 rat (arteriolipidosis-prone rat); ND: normal diet; HFCD: high fat and high cholesterol-containing diet; IMGs: iron metabolism-related genes; Dcytb: duodenal cytochrome b; DMT1: divalent metal transporter 1; TfR1: transferrin receptor 1; FPN1: ferroportin 1; HE: hematoxylin and eosin; IHC: immunohistochemistry; mRNA: messenger RNA; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; RT-qPCR: real-time reverse transcription-quantitative polymerase chain reaction; LPS: lipopolysaccharide; HAMP: hepcidin antimicrobial peptide; si-C: control siRNA; si-HAMP: siRNA against HAMP.

## Author contributions

**Study concept and design/acquisition of data/analysis and interpretation of data/statistical analysis:** Teruhisa Higuchi, Mitsuhiro Moriyama, Akiko Fukushima, Tatsuo Kanda, Masahiko Sugitani, Akiko Tsunemi, Takahiro Ueno and Noboru Fukuda; **Drafting of the manuscript:** Teruhisa Higuchi, Mitsuhiro Moriyama and Tatsuo Kanda; **Critical revision of the manuscript for important intellectual content:** Teruhisa Higuchi, Mitsuhiro Moriyama, Akiko Fukushima, Hiroshi Matsumura, Shunichi Matsuoka, Tatsuo Kanda, Masahiko Sugitani, Akiko Tsunemi, Takahiro Ueno, and Noboru Fukuda. **All authors reviewed and agreed to this information before submission.**

## ACKNOWLEDGMENTS

We thank Prof. Keisuke Hino and Prof. Takuji Gotoda for valuable discussions, and Ms. Kayo Iwaguchi and Ms. Shinobu Arai for their excellent assistance.

## CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

## FUNDING

This work was not supported by any funding.

## REFERENCES

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc.* 1980; 55:434-438.
2. Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. *Hepatol Res.* 2012; 42:368-375.
3. Hashimoto E, Yatsuji S, Tobari M, Tani M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *J Gastroenterol.* 2009; 44:89-95.
4. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. *J Gastroenterol.* 2009; 44:1190-1194.
5. Jiang CM, Pu CW, Hou YH, Chen Z, Alanazy M, Hebbard L. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. *World J Gastroenterol.* 2014; 20:16464-16473.
6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology.* 2010; 51:1820-1832.
7. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, et al. Inflammation-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature.* 2012; 482:179-185.
8. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. *Nat Rev Gastroenterol Hepatol.* 2010; 7:691-701.
9. Okubo H, Sakoda H, Kushiya A, Fujishiro M, Nakatsu Y, Fukushima T, Matsunaga Y, Kamata H, Asahara T, Yoshida Y, Chonan O, Iwashita M, Nishimura F, et al. *Lactobacillus casei* strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. *Am J Physiol Gastrointest Liver Physiol.* 2013; 305:G911-G918.
10. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. *Hepatology.* 2014; 59:328-339.
11. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. *Gastroenterology.* 1995; 108:218-224.
12. Day CP, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology.* 1998; 114:842-845.
13. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, Amin AI, Burt AD, Kumar S, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. *J Inflamm (Lond).* 2010; 7:15.
14. Chino S, Moriyama M, Matsumura H, Ono Y, Arakawa Y. Clinical pathological significance of iron metabolism with chronic hepatitis C patients. *Hepatol Res.* 2002; 24:245-55.
15. Nirei K, Matsuoka S, Nakamura H, Matsumura H, Moriyama M. Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C. *Intern Med.* 2015; 54:107-117.
16. Lombardi R, Pisano G, Fargion S. Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD. *Int J Mol Sci.* 2016; 17:548.
17. Anderson GJ, Vulpe CD. Mammalian iron transport. *Cell Mol Life Sci.* 2009; 66:3241-3261.
18. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, Anderson GJ. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. *Nat Genet.* 1999; 21:195-199.
19. Yoshida Y, Fukuda N, Maeshima A, Yamamoto C, Matsumoto T, Ueno T, Nojima Y, Matsumoto K, Soma M. Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats. *J Hypertens.* 2011; 29:91-101.
20. Ueno T, Fukuda N, Nagase H, Tsunemi A, Tahira K, Matsumoto T, Hiraoka-Yamamoto J, Ikeda K, Mitsumata M, Sato Y, Soma M, Matsumoto K, Yamori Y. Atherogenic dyslipidemia and altered hepatic gene expression in SHRSP.Z-Leprfa/IzmDmcr rats. *Int J Mol Med.* 2009; 23:313-320.
21. Kitamori K, Naito H, Tamada H, Kobayashi M, Miyazawa D, Yasui Y, Sonoda K, Tsuchikura S, Yasui N, Ikeda K, Moriya T, Yamori Y, Nakajima T. Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. *Environ Health Prev Med.* 2012; 17:173-182.
22. Moriya T, Kitamori K, Naito H, Yanagiba Y, Ito Y, Yamagishi N, Tamada H, Jia X, Tsuchikura S, Ikeda K, Yamori Y, Nakajima T. Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat. *Environ Health Prev Med.* 2012; 17:444-456.

23. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. *Semin Liver Dis.* 2001; 21:3-16.
24. Sammarco MC, Ditch S, Banerjee A, Grabczyk E. Ferritin L and H subunits are differentially regulated on a post-transcriptional level. *J Biol Chem.* 2008; 283:4578-4587.
25. Ziv K, Meir G, Harmelin A, Shimoni E, Klein E, Neeman M. Ferritin as a reporter gene for MRI: chronic liver over expression of H-ferritin during dietary iron supplementation and aging. *NMR Biomed.* 2010; 23:523-531.
26. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, Iannelli A, Staccini-Myx A, Casanova D, Ben Amor I, Saint-Paul MC, Huet PM, Sadoul JL, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. *Gastroenterology.* 2006; 131:788-796.
27. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, Andrews NC. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. *Cell Metab.* 2005; 1:191-200.
28. Bardou-Jacquet E, Island ML, Jouanolle AM, Détivaud L, Fatih N, Ropert M, Brissot E, Mosser A, Maisonneuve H, Brissot P, Loréal O. A novel N491S mutation in the human SLC11A2 gene impairs protein trafficking and in association with the G212V mutation leads to microcytic anemia and liver iron overload. *Blood Cells Mol Dis.* 2011; 47:243-248.
29. Constantine CC, Anderson GJ, Vulpe CD, McLaren CE, Bahlo M, Yeap HL, Gertig DM, Osborne NJ, Bertalli NA, Beckman KB, Chen V, Matak P, McKie AT, et al. A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis. *Br J Haematol.* 2009; 147:140-149.
30. Latunde-Dada GO, Simpson RJ, McKie AT. Duodenal cytochrome B expression stimulates iron uptake by human intestinal epithelial cells. *J Nutr.* 2008; 138:991-995.
31. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology.* 2009; 49:1877-1887.
32. Arakawa Y, Moriyama M, Taira M, Hayashi N, Tanaka N, Okubo H, Sugitani M. Molecular analysis of hepatitis D virus infection in Miyako Island, a small Japanese island. *J Viral Hepat.* 2000; 7:375-381.
33. Sasaki R, Kanda T, Wu S, Nakamoto S, Haga Y, Jiang X, Nakamura M, Shirasawa H, Yokosuka O. Association between hepatitis B virus and MHC class I polypeptide-related chain A in human hepatocytes derived from human-mouse chimeric mouse liver. *Biochem Biophys Res Commun.* 2015; 464:1192-1195.
34. Sasaki R, Kanda T, Nakamura M, Nakamoto S, Haga Y, Wu S, Shirasawa H, Yokosuka O. Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells. *PLoS One.* 2016; 11:e0146314.
35. Hose C, Kaur G, Sausville EA, Monks A. Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation. *Clin Cancer Res.* 2005; 11:6370-6381.

## 論文の要旨・要約

論文題名 : Association of mRNA expression of iron metabolism-associated genes  
and progression of non-alcoholic steatohepatitis in rats

(非アルコール性脂肪肝炎モデルラットにおける病態進展と

鉄代謝関連遺伝子発現に関する検討)

## 要旨

## 【背景と目的】

非アルコール性脂肪肝炎(NASH)と鉄代謝との関連が報告されている(1)。本研究では NASH における肝および上部・下部小腸組織鉄代謝関連遺伝子発現変化を明らかにすることを目的とした。

## 【対象と方法】

脳卒中易発症高血圧自然発症ラット(SHRSP)の亜系統 NASH モデルラット (SHRSP5) で肝および上部・下部小腸組織における鉄代謝関連遺伝子発現を検討した。コントロール飼料(ND)で飼育した 5 週齢の SHRSP5 に高脂肪高コレステロール含有飼料 (HFCD) (2) または ND を投与し、それぞれ HFCD 群および ND 群とした。12 週齢および 19 週齢のラットの肝および上部・下部小腸組織における鉄代謝関連遺伝子発現を比較検討した。また ND で飼育した 5 週齢の SHRSP5 における遺伝子発現とも比較検討した。鉄代謝関連遺伝子発現は mRNA レベルおよび蛋白レベルを Real-Time

RT-PCR 法および免疫組織染色・Western blot 法によりそれぞれ検討した。

### 【結果】

鉄代謝関連遺伝子の検討では、肝組織 Duodenal cytochrome b (Dcytb)、Divalent metal transporter 1 (DMT1)、Ferroportin 1 (FPN1)、Hephaestin、Transferrin receptor 1 (TfR1) の発現は、ND 群と比較し HFCD 群において 12 週齢および 19 週齢でも mRNA レベルで増加していた。一方、Hepcidin の発現は HFCD 群と比較して ND 群において 12 週齢および 19 週齢でも mRNA レベルで増加していた。鉄吸収および排泄を促進するとされる DMT1 および TfR1 の mRNA 発現は、小腸組織で増加していた。HFCD 群の小腸上皮粘膜では、形質細胞・好酸球の浸潤が特に観察され、空胞の増加が目立った。ヒト肝癌細胞で抗菌ペプチド Hepcidin を siRNA によりノックダウンするとフェリチン H 鎖発現が増加した。このことは肝細胞における Hepcidin 産生と鉄沈着に直接相互作用があることを示唆している。

### 【考察と結論】

鉄は門脈を介して肝細胞へ輸送されることが知られている。この NASH モデルラットでは、HFCD 負荷により、小腸組織で鉄代謝関連遺伝子発現変化を伴っており、鉄吸収・排泄異常が起きている可能性がある。また肝組織でも鉄代謝関連遺伝子発現変化が起きていた。肝および上部・下部小腸組織における鉄代謝関連遺伝子が、NASH の病態進展に伴い変化することを明らかにした。

## 要約

### 【背景と目的】

非アルコール性脂肪性肝炎(NASH)は、アルコールを摂取しないにも拘わらずアルコール性肝障害に類似した肝組織所見を呈する肝疾患であり、比較的新しい疾患概念である(3)。近年 NASH の症例数及び NASH 関連肝細胞癌 (Hepatocellular carcinoma) の症例数は増加している(4-6)。NASH は、肥満や糖尿病など生活習慣の問題を含む様々な因子と関連があると考えられている。特に、酸化ストレス・過酸化脂質・鉄過剰・インスリン抵抗性・炎症性サイトカインの上昇や遺伝子異常が原因として報告されているが、その病態進展機序に関する詳細な点は不明である。

肝臓には機能血管の一つとして門脈があり腸から血流が流れ込んでいる。腸から流入する様々な物質が肝疾患の病態形成に関与している。腸の微小環境は、NASH や非アルコール性脂肪性肝疾患 (NAFLD) の発症の一因となり得ると考えられている。

今までに、NASH と鉄代謝との関連が報告されている(1)。我々も C 型慢性肝炎におけるフェリチンや肝貯蔵鉄が肝生検組織所見における炎症や線維化と密接に関連し(7)、瀉血療法により肝貯蔵鉄を減らすことにより肝細胞癌発生を減らすことが可能であることを明かにしてきた(8)。NAFLD でも肝障害の重症度マーカーとしての血清フェリチンの有用性が報告されている(9)。

鉄吸収部位である小腸粘膜や肝臓の鉄吸収排泄が NASH 発症や病態進展に関与している可能性があり、NASH の鉄代謝関連遺伝子(Iron metabolism-associated genes)発現

状態を比較検討する必要があると考えた。今回我々は NASH モデルとして、脳卒中易発症高血圧自然発症ラット [stroke-prone spontaneously hypertensive (SHRSP)] の亜系統ラット(SHRSP5)を用いた。そして肝および上部・下部小腸組織における鉄代謝関連遺伝子の発現状態を比較した。

### 【対象と方法】

SHRSP ラットの亜系統 NASH モデルラット (SHRSP5) で肝および上部・下部小腸組織における鉄代謝関連遺伝子発現を検討した。SHRSP5 ラットは Wistar-Kyoto ラット由来の SHRSP に高脂肪高コレステロール含有飼料(HFCD) (2)を負荷し脂質異常の強い個体を交配して得られた亜系統で、動脈脂肪沈着や肝線維化を来し食事誘発性の NASH を発症する特徴を有する。コントロール飼料(ND)で飼育した 5 週齢の SHRSP5 に HFCD または ND を投与し、それぞれ HFCD 群および ND 群とした(図 1)。




図 1 本研究におけるラット食餌負荷プロトコール

鉄代謝関連遺伝子[Transferrin receptor 1 (TfR1)、Duodenal cytochrome b (Dcytb)、Divalent metal transporter 1 (DMT1)、Ferroportin 1 (FPN1)、Hepcidin、Hephaestin] の発現は mRNA レベルおよび蛋白レベルを Real-Time RT-PCR 法および免疫組織染色や Western blot 法によりそれぞれ検討した。

TfR1 は骨髄由来系の細胞に比較的高発現しているが、エンドサイトーシスにより Transferrin から細胞内に鉄を取り込むのに重要である。Dcytb は  $\text{Fe}^{3+}$  を  $\text{Fe}^{2+}$  に還元し、腸管で鉄吸収促進に働く。また鉄欠乏により腸管における Dcytb が増加することが知られている。DMT1 は幼若赤血球での発現が高いことが知られていて、 $\text{Fe}^{2+}$  を細胞内に取り込む。 $\text{Fe}^{2+}$  の輸送に関与する FPN1 は肝細胞を含む基底膜側に存在する膜貫通型蛋白であり、 $\text{Fe}^{2+}$  を細胞から排泄する。Hephaestin は小腸粘膜に高発現しており、食事の鉄を腸管細胞から門脈血中に移送する。

Hepcidin はヒトでは HAMP 遺伝子によりコードされおり最終産物は 25 アミノ酸である。肝臓が最大の産生臓器であるが、これまで Hepcidin は腸管上皮に存在する鉄排泄を促進する鉄代謝関連遺伝子の一つ FPN1 に結合し鉄輸送を阻害することが知られている(10)。また肝臓において蛋白レベルで発現がみられる。そこで、これら 6 つの鉄代謝関連遺伝子に注目し検討した。

12 週齢および 19 週齢のラットの肝および上部・下部小腸組織における鉄代謝関連遺伝子発現を比較検討した。また ND で飼育した 5 週齢の SHRSP5 における遺伝子発現とも比較検討した。

肝臓・小腸組織学的検討に用いた抗体・方法は別途報告した通りである (11)。

体重測定は7、9、11、13、15、17 および 19 週齢においてそれぞれ行った。肝臓・脾臓重量測定は12 週齢と 19 週齢で比較検討した。鉄組織含有量測定は 50 mg の凍結組織を用いて Inductively Coupled Plasma Mass Spectrometry-Atomic emission spectrophotometer (ICP-AES, Shimazu ICP8100, Kyoto, Japan)で測定した。

血清生化学的検査は血清総ビリルビン、直接ビリルビン、AST、ALT、ALP、 $\gamma$ -GTP、総コレステロール、中性脂肪、遊離脂肪酸を測定した。NASH の組織学的分類は Brunt 分類に従った(12)。

またヒト肝癌細胞株 Huh7、HepG2 細胞で HAMP に対する siRNA を用いたノックダウンを行い、その効果について Toll-like receptor 関連 84 遺伝子を real-time PCR array を用いて網羅的に調べた。

統計学的解析は Turkey-Kramer test、肝組織は Steel-Dwass test を用いて行い、 $P < 0.05$  を有意差ありと判定した。

## 【結果】

### (1) ラット体重、肝臓および脾臓重量の変化について

HFCD 群の体重増加は ND 群と比較し低下していた。HFCD 群の全ラットで研究期間中頻回に下痢がみられた。12 週齢および 19 週齢における平均肝重量に関しては ND

群と比較し HFCD 群では有意に重かった。12 週齢および 19 週齢における平均脾重量  
 に関しても ND 群と比較し HFCD 群では有意に重かった。

## (2) 肝および小腸組織における鉄含量について

ND 群の肝臓の鉄含量のほうが HFCD 群と比較し多い結果であった (下表)。

表 ラット肝および上部・下部小腸組織における鉄含量 (ppb) [Normal diet

(ND)群と High fat and high cholesterol-containing diet (HFCD)群の比較]

週齢 (週)	肝臓 (n=19)		上部小腸組織 (n=6)		下部小腸組織 (n=6)	
	ND (n=12)	HFCD (n=7)	ND (n=4)	HFCD (n=2)	ND (n=4)	HFCD (n=2)
5	20.2±5.25 (n=4)	N.D.	8.45 (n=2)	N.D.	8.75 (n=2)	N.D.
12	19.0±2.82 (n=4)	9.58±0.94 <sup>a</sup> (n=4)	N.D.	N.D.	N.D.	N.D.
19	26.2±2.92 (n=4)	11.13±1.44 <sup>a</sup> (n=3)	8.20 (n=2)	7.20 <sup>a</sup> (n=2)	8.70 (n=2)	7.30 <sup>a</sup> (n=2)

Data are shown as mean ± standard deviation. N.S., not statistically significant  
 difference; <sup>a</sup>ND vs. HFCD, P<0.05 by Turkey-Klamar test; N.D., not done.

### (3) 血液生化学検査の検討

19 週齢における血清総ビリルビン値、 $\gamma$ -GTP 値、遊離脂肪酸値は ND 群と比較し HFCD 群で有意に高値であった。12 週齢における血清総コレステロール値は ND 群と比較し HFCD 群で有意に高値であった。12 週齢および 19 週齢における血清 AST 値、ALT 値、ALP 値は ND 群と比較し HFCD 群で有意に高値であった。

### (4) 肝臓の病理学的変化について

ND 群では 12 週齢および 19 週齢において高度肝線維化がみられなかった。肝細胞にびまん性の脂肪滴が観察された。しかし、NASH によく見られる類洞周囲線維化、肝細胞周囲線維化や中心静脈周囲線維化などはみられなかった(Brunt 分類 A1/F1 および A1/F2)。一方、HFCD 群では 12 週齢において肝細胞にびまん性の脂肪滴が多数観察され、軽度類洞周囲線維化、中等度肝細胞周囲線維化や中等度中心静脈周囲線維化などがみられた。また肝細胞バルーニングや Mallory 体もみられた(Brunt 分類 A1/F1)。HFCD 群では 19 週齢でこれらの所見が進行し典型的な NASH の所見を呈していた(Brunt 分類 A3/F3)。

### (5) 上部・下部小腸組織の病理学的変化について

本研究では上部および下部小腸組織をそれぞれ十二指腸近傍および回腸近傍と仮定した。HFCD 群 19 週齢の上部小腸組織では炎症細胞浸潤は ND 群と同様の所見で

あったが、細胞質に空胞を持った細胞数が増加していた。この空胞は Sudan III 染色で染まらず脂肪滴とは異なっていた。

HFCD 群 19 週齢の下部小腸組織では組織構造はほぼ保たれていたが、中等度の慢性炎症所見を認めた。細胞質に空胞を持った細胞は上部小腸組織と同程度に観察された。また ND 群と比較して胚細胞の増加が目立った。

#### (6) 肝臓の鉄代謝関連遺伝子の変化について

肝組織での Dcytb、DMT1、FPN1、Hephaestin、TfR1 の発現は、ND 群と比較して HFCD 群において 12 週齢および 19 週齢でも mRNA レベルで増加していた。一方 Hecpudin の発現は HFCD 群と比較して、ND 群において 12 週齢および 19 週齢でも mRNA レベルで増加していた。

#### (7) 上部・下部小腸組織の鉄代謝関連遺伝子の変化について

5 週齢で上部小腸組織と比較し Dcytb は下部小腸組織で有意に発現が高い遺伝子であった ( $p < 0.05$ )。一方 5 週齢で下部小腸組織と比較し、FPN1 は唯一上部小腸組織での発現が高い遺伝子であった ( $p < 0.05$ )。

ND 群では上部小腸組織と比較し Dcytb、Hepcidin、TfR1 および Hephaestin は下部

小腸組織で発現が高い傾向を示した。一方 DMT1 と FPN1 は下部小腸組織で発現が低い傾向を示した。

HFCD 群では上部小腸組織と比較し Dcytb、DMT1、TfR1 および Hephaestin は下部小腸組織で発現が高い傾向を示した。一方 Heparidin と FPN1 は下部小腸組織で発現が低い傾向を示した。

5 週齢と比較して、ND 群と HFCD 群の上部小腸組織では、Dcytb は低下傾向を示した唯一の遺伝子であった。一方 5 週齢と比較して、ND 群と HFCD 群の上部小腸組織では、DMT1、Heparidin および TfR1 は増加傾向を示した。一方 5 週齢と比較して、ND 群と HFCD 群の下部小腸組織では、DMT1、TfR1 および Hephaestin は増加傾向を示した。

#### (8) Western blot 法による鉄代謝関連蛋白の解析

肝組織の検討では 5 週齢と比較して、19 週齢では Dcytb、DMT1、TfR1 および FPN1 の発現が高く Heparidin の発現が低下していた。上部小腸組織の検討では 5 週齢と比較して、HFCD 群で、Dcytb、DMT1 および FPN1 の発現増加がみられた。一方、Hephaestin は唯一発現低下を示した。下部小腸組織の比較では 5 週齢と比較して、19 週齢の ND 群と HFCD 群で DMT1 の発現の増加がみられた。一方 5 週齢と比較して、HFCD 群で Dcytb と FPN1 発現が低下していた。これらの結果は免疫組織染色でも確認された。

### (9) ヒト肝癌細胞株に対する Heparin ノックダウンの影響

ヒト肝癌細胞株 Huh7 細胞および HepG2 細胞にて Heparin (HAMP) を siRNA によりノックダウンするとフェリチン H 鎖発現が増加した。Heparin 産生と鉄沈着に直接相互作用があることを示唆している。更に Toll-like receptor 関連遺伝子を PCR array で網羅的に解析すると HAMP を siRNA によりノックダウンした Huh7 細胞では IL-1 $\beta$  および Colony stimulating factor 3 (CSF3) がそれぞれ 3 倍および 2.5 倍と発現が増加傾向にあった。また TNF および IL-1 $\alpha$  はそれぞれ 2.3 倍および 2.2 倍と発現が減少傾向にあった。肝細胞で HAMP mRNA はサイトカイン遺伝子発現と関連している可能性が示唆された。

### 【考察】

HFCD 群 19 週齢の肝臓では、DMT1 及び FPN1 の mRNA 発現増加により鉄の吸収・排泄が促進される可能性が示唆された(図 2)。また、Heparin の発現は ND で飼育した 5 週齢と比較し肝細胞の細胞質及び細胞膜・間葉細胞で発現増加していた。HFCD 群の肝細胞内で鉄沈着が促進している可能性が示唆された。

HFCD 群 19 週齢は 5 週齢に比べて、小腸下部の Dcytb の発現は減少し、小腸上部での Dcytb の発現も減少傾向であった。小腸上部でのみ FPN1 発現が増加し、DMT1 及び TfR1 の発現は上部・下部で増加し、Hephaestin 発現は下部でのみ増加した。

HFCD 群の小腸上皮細胞では、DMT1・FPN1・TfR1 の発現増加により鉄の吸収・排泄が促進している可能性が示唆された。




図2 HFCD 群ラットにおける鉄代謝関連遺伝子の変化（矢印: ND 群ラットと比較して mRNA レベルで増加したもの）

HFCD 群の小腸下部では Dcytb 及び FPN1 の発現が経時的に減少したが、DMT1 及び Hephaestin の発現は増加した。Fe<sup>2+</sup>を運搬し肝臓など固形臓器に複合体として鉄を結合すると推定された。鉄代謝関連遺伝子の蛋白質発現は、組織学的損傷又は変性のある小腸上皮細胞で増強する傾向があった。

注目すべき点として Hephastin mRNA 発現が肝臓および下部小腸組織で著明に増加していた(図 2)。NASH 発症に Hephastin が重要な役割を担っている可能性が示唆された。

この NASH モデルでは鉄吸収が促進されていることが推定され、HFCD による腸上皮細胞障害の結果によるものと考えられた。過剰鉄は門脈を介して肝細胞に運搬される。

この NASH モデルでは鉄代謝関連遺伝子の発現変化を認め、鉄吸収や排泄の異常が推察された。また Hephastin 産生と肝細胞鉄沈着の関連も示唆された。

これらのことから、肝および上部・下部小腸組織における鉄代謝関連遺伝子発現が NASH 進展に重要な役割を担っていることが示唆された。

**【参考文献】**

1. Du SX, et al. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis. *Lipids Health Dis.* 2017 Dec 2;16(1):228. doi: 10.1186/s12944-017-0613-4
2. Kitamori K, et al. Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. *Environ Health Prev Med.* 2012 May; 17(3): 173–182.
3. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc.* 1980 Jul;55(7):434-8.
4. Nagaoki Y, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. *Hepatol Res.* 2012 Apr;42(4):368-75. doi: 10.1111/j.1872-034X.2011.00929.x.
5. Hashimoto E, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *J Gastroenterol.* 2009;44 Suppl 19:89-95. doi: 10.1007/s00535-008-2262-x.
6. Kawada N, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. *J Gastroenterol.* 2009;44(12):1190-4. doi: 10.1007/s00535-009-0112-0.
7. Chino S, et al. Clinical pathological significance of iron metabolism with chronic hepatitis C patients. *Hepatol Res.* 2002 Nov;24(3):245.
8. Nirei K, et al. Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C. *Intern Med.* 2015;54(2):107-17.

9. Lombardi R, et al. Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD. *Int J Mol Sci.* 2016 Apr 12;17(4):548.
10. Gulec S, et al. Mechanistic and regulatory aspects of intestinal iron absorption. *Am J Physiol Gastrointest Liver Physiol.* 2014 Aug 15;307(4):G397-409. doi: 10.1152/ajpgi.00348.2013.
11. Higuchi T, et al. Association of mRNA expression of iron metabolism-associated genes and progression of non-alcoholic steatohepatitis in rats. *Oncotarget.* 2018 May 25;9(40):26183-26194. doi: 10.18632/oncotarget.25488.
12. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. *Semin Liver Dis.* 2001;21:3-16.